ПОИСК ПО САЙТУ 
поиск по ресурсному центру The problem with antiretroviral therapy in the Republic of Kyrgyzstan is still acute.
Aybar Sultangaziyev, the Director of the Partner Network Association and the leader of the consortium of NGOs of the regional PARTNERSHIP program, said that his team is preparing a lawsuit against Abbott pharmaceutical company.
The reason for filing a lawsuit was the issuance of a license to the generic company for the production of generics (lopinavir/ritonavir) with geographical restrictions on their sale in Kyrgyzstan.
“This contradicts the country’s legislation and WTO rules, which envisage the purchase of a medication without restrictions, as soon as the manufacturing of generics with the permission of the patent holder started across the world”, Mr. Sultangaziev said.
According to the leader of the Partner Network Association in the Kyrgyz Republic, the problem with ARV drugs remains acute. In the fight against the HIV/AIDS epidemic, the Ministry of Health should show genuine engagement and participation. It is this department of the country that can make medicines available and ensure affordable prices for them.
“In 2 years we must increase the coverage of people with AIDS treatment. We found out that Abbott pharmaceutical company is making surplus profits from the procurement of medicines by the countries. With the support of Global Fund, we bought a drug at $60 per a pack, and you could buy other drugs that are equally effective for $10 per a pack. It turns out that in 2 years the company gained at least $300 thousand”, said Aybar Sultangaziev.
